

## **VII. BIBLIOGRAFIA**



## BIBLIOGRAFIA

ANDERSON, G.D. (1998) - A mechanistic approach to antiepileptic drug interactions. **Ann. Pharmacother.** 32 (1998) 554-63.

BENES, J. [et al.] (1999) - Anticonvulsant and Sodium Channel-Blocking Properties of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine-5-carboxamide Derivatives. **J. Med. Chem.** 42 (1999) 2582-2587.

BERTRAND, P.; DUBAS, F. (1990) - Épilepsies: étiologie, diagnostic, évolution, pronostic et principes du traitement. **Nouv. Quest.** 2:6 (1990) 23-29.

BESAG, F.M.C. [et al.] (1998) – Carbamazepine toxicity with Lamotrigine: pharmacokinetic or pharmacodynamic interaction? **Epilepsia.** 39:2 (1998) 183-187.

BIALER, M. (1993) - Comparative pharmacokinetics of the newer antiepileptic drugs. **Epilepsy Res.** 24:6 (1993) 441-452.

BIALER, M. (2002) - New Antiepileptic Drugs Currently in Clinical Trials: Is There a Strategy in Their Development? **Ther. Drug Monit.** 24 (2002) 85-90.

BIALER, M. [et al.] (2002) - Progress report on new antiepileptic drugs : a summary of the Sixth Eilat Conference (EILAT VI). **Epilepsy Res.** 51 (2002) 31-71.

BLAISE, F.D.; BOURGEOIS, M.D. (2000) - Pharmacokinetic properties of current antiepileptic drugs: what improvements are needed? **Neurology.** 55: suppl. 3 (2000) S11-S16.

BOROWICZ, K.K. [et al.] (2000) - Low propensity of conventional antiepileptic drugs for interaction with felbamate against maximal electroshock-induced seizures in mice. **J. Neural. Transm.** 107 (2000) 733-743.

BOROWICZ, K.K. [et al.] (2002) - Effect of Gabapentin on the Anticonvulsant Activity Of Antiepileptic Drugs against Electroconvulsions in Mice: An Isobolographic Analysis. **Epilepsia.** 43:Suppl. 9 (2002) 956-963.

BRODIE, M.J. (2001) – Do we need any more antiepileptic drugs? **Epilepsy Res.** 45 (2001) 3-6.

BURSTEIN, A.H. (1995) - Evaluation of new drugs: Lamotrigine. **Pharmacotherapy.** 15:2 (1995) 129-143.

CASTEL-BRANCO, M.M. [et al.] (2003) - Anticonvulsant profile of lamotrigine in rats following a single intraperitoneal dose. **J. Veterinary Pharmacol. Ther.** Aug. 26:Suppl. 1 (2003) 167-168.

CASTEL-BRANCO, M.M. (2002) - **Caracterização neurofarmacocinética da lamotrigina em ratos.** Coimbra. Laboratório de Farmacologia; Faculdade de Farmácia, Universidade de Coimbra, 2003.Tese de doutoramento.

CLEMENS, B.; MÉNES, A.; NAGY, Z. (2004) – Objective assessment of neurotoxicity while shifting from carbamazepine to oxcarbazepine. **Acta Neurol. Scand.** 109 (2004) 324-329.

CZUCZWAR, S.J.; BOROWICZ K.K. (2002) – Polytherapy in epilepsy: the experimental evidence. **Epilepsy Res.** 52 (2002) 15-23.

DALBY, N.O.; NIELSON, E.B. (1997) - Comparison of the preclinical anticonvulsant profiles of Tiagabine, Lamotrigine, Gabapentin and Vigabatrin. **Epilepsy Res.** 28 (1997) 63-72.

DE SARRO, G. [et al.] (2001) - Influence or retigabine on the anticonvulsant activity of some antiepileptic drugs against audiogenic seizures in DBA/2 mice. **Nauny-Schmiedeberg's Arch. Pharmacol.** 363 (2001) 330-336.

DECKERS, C.L.P. [et al.] (2000) - Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewd. Nov. 41:11 **Epilepsia.** (2000) 1364-74.

DECKERS, C.L.P. [et al.] (2002) - Current limitations of antiepileptic drug therapy: a conference review. **Epilepsy Res.** 53 (2002) 1-17.

DIAS, M.S. (1992) – Epilepsia: Considerações sobre a doença e o seu tratamento. **Farmácia Port.** 76:7/8(1992) 37-43.

DICHTER, M.A.; BRODIE, M.J. (1996) - Drug Therapy: New Antiepileptic drugs. **N. Engl. J. Med.** Jun. 334:24 (1996) 1583-1590.

DREIFUSS, F.E. (1997) - Classification of Epileptic Seizures. In ENGEL, J.; PEDLEY, T.A. ed. lit. - **Epilepsy: A Comprehensive Textbook**. Philadelphia: Lippincott-Raven Publishers, Raven Publishers, Vol. 1, chapter 44 (1997) 517-524.

ELWES, R.D.C.; BINNIE, C.D. (1996) - Clinical Pharmacokinetics of Newer Antiepileptic Drugs: Lamotrigine, Vigabatrin; Gabapentin and Oxcarbazepine. **Clin. Pharmacokinet.** Jun. 30:6 (1996) 403-415.

ENGEL, J.J.; PEDLEY, T.A. (1997) - Introduction: What is Epilepsy? In ENGEL, J.; PEDLEY, T.A. ed. lit. - **Epilepsy: A Comprehensive Textbook**. Philadelphia: Lippincott-Raven Publishers. Vol. 1: Chapter 1 (1997) 1-7.

ESTEVES, A.; GARRETT, C. (2001) - Antiepilépicos. In OSSWALD, W.; GUIMARÃES, S. – **Terapêutica Medicamentosa e suas Bases Farmacológicas**. 4<sup>a</sup>ed. Porto: Porto Editora, (2001) Cap.18: p.222-226.

FERRENDELLI, J.A. (2001) - Concerns with antiepileptic drug initiation: safety, tolerability and efficacy. **Epilepsia**. 42:Suppl. 4 (2001) 28-30.

FERRENDELLI, J.A. (1999) - Pharmacology of Antiepileptic Drug Polypharmacy. **Epilepsia**. 40:Suppl. 5 (1999) S81-S83.

FERRENDELLI, J.A. (1995) - Relating pharmacology to clinical practice: The pharmacologic basis of rational polypharmacy. **Neurology**. 45: Suppl. 2 (1995) S12-S16.

FILIPE, C.N. (1997) – Mecanismos básicos das epilepsias. **Rev Port Pedopsiq.** 12 (1997) 29-46.

FIRMINO, H.; MARQUES, R. (1991) - Aspectos psicossociais do Doente epiléptico. **Médice.** 9 (1991)11-13.

FITTON, A.; GOA, K.L. (1995) - Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy. **Drugs.** 50:4 (1995) 691-713.

GESSNER, P.K. (1995) - Isobolographic analysis of interactions: an update on applications and utility. **Toxicology.** 105 (1995) 161-179.

GILMAN, J.T. (1995) - Lamotrigine: an antiepileptic agent for the treatment of partial seizures. **Ann. Pharmacother.** 29 (1995) 144-51.

GIL-NAGEL, A. (2003) – Review of new antiepileptic drugs as initial therapy. **Epilepsia.** 44 (Suppl. 4) (2003) 3-10.

GOA, K.L.; ROSS, S.R.; CHRISP P. (1993) - Lamotrigine: a review of its pharmacological and clinical efficacy in epilepsy. **Drugs.** 46:1 (1993) 152-176.

GOODMAN, L.S. [et al.] (1958) - Comparison of maximal seizures evoked by pentylenetetrazol (metrazol) and electroshock in mice, and their modification by anticonvulsants. **J. Pharmacol. Exp. Ther.** 108 (1958) 428-436.

GRAVES, N.M.; LEPIK, I.E. (1991) - Antiepileptic medications in development. **Ann. Pharmacother.** 25 (1991) 978-86.

GUBERMAN, A. (1998) - Monotherapy or polytherapy for Epilepsy? **Can. J. Neurol. Sci.** 25:Suppl. 4 (1998) S3-S8.

HACHAD, H.; RAGUENEAU-MAJLESSI, I.; LEVY, R.H. (2002) - New Antiepileptic Drugs: Review on Drug Interactions. **Ther. Drug. Monit.** 24:1 (2002) 91-103.

HULSMAN, J. A. R. J. (1995) – Effects of felbamate on the pharmacokinetics of oxcarbazepine. **Clin. Pharmacol. Ther.** 58 (1995) 383-389.

KALIS, M.M.; HUFF, N.A. (2001) - Oxcarbazepine, an antiepileptic agent. **Clin. Ther.** 23: 5 (2001) 680-700.

KÄLVIÄINEN, R.; KERÄNEN, T.; RIEKKINEN, SR P.J. (1993) - Place of the Newer Antiepileptic Drugs in the Treatment of epilepsy. **Drugs**. 46:6 (1993) 1009-1024.

KUBOVA, H.; MARES, P. (1993) - Anticonvulsant action of Oxcarbazepine, Hydroxycarbazepine, and Carbazepine against metrazol-induced motor seizures in developing rats. **Epilepsia**. 34:1 (1993) 188-192.

KWAN, P.; BRODIE, M.J. (2000) – Epilepsy after the first drug fails: substitution or add-on? **9 Epilepsy Quarterly**. (2000) 464-468.

KWAN, P. (2001) - Management of Patients with Newly Diagnosed Epilepsy. **Epilepsy Quarterly**. 9:2 (2001) 10-14.

LAFFAN, R.J.; SWINYARD, E.A.; GOODMAN, L.S. (1957) - Stimulus intensity, maximal electroshock seizures, and potency of anticonvulsants in rats. **Arch. Int. Pharmacodyn. Ther.** 111 (1957) 60-69.

LEACH, J.P. (2000) – Antiepileptic drugs: safety in numbers? **Seizure**. 9 (2000) 170-178.

LEPPIK, I. E. (2000) - Monotherapy and polypharmacy. **Neurology** 55: Suppl. 3 (2000) S25-S29.

LÖSCHER, W.; FASSBENDER, C.P.; NOLTING, B. (1991) - The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsante drugs. II. Maximal Electroshock Seizure Models. **Epilepsy Res.** 8 (1991) 79-94.

LÖSCHER, W.; SCHMIDT, D. (1994) - Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? **Epilepsy Res.** 17 (1994) 95-134.

LÖSCHER, W.; SCHMIDT, D. (1998) - Which animals models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. **Epilepsy Res.** 2 (1998) 145-181

LÖSCHER, W. (1998) - New visions in the pharmacology of anticonvulsions. **Eur. J. Pharmacol.** 342 (1998) 1-13.

LÖSCHER, W. (2002) – Current status and future directions in the pharmacotherapy of epilepsy. **Trends Pharmacol. Sci.** 23: 3 (2002) 113-118.

LÖSCHER, W.; SCHMIDT, D, (2002) – New horizons in the development of antiepileptic drugs. **Epilepsy Res.** 50 (2002) 3-16.

LOWENSTEIN, D.H. (2002) – Convulsões e Epilepsia. In HARRISON,T.R.- **Medicina Interna**. Rio de Janeiro: Mc Graw Hill; 15<sup>a</sup> ed., 2002. Vol II chapter 360: p.2501-2517.

LUSZCZKI, J.J. [et al.] (2003a) - Interactions Between Oxcarbazepine and Conventional Antiepileptic Drugs in the Maximal Electroshock Test in Mice: An Isobolographic Analysis. **Epilepsia.** 44:4 (2003a) 489-499.

LUSZCZKI, J.J. [et al.] (2003b) - Interactions of Lamotrigine with Topiramate and First-generation Antiepileptic Drugs in the Maximal Electroshock Test in Mice: An Isobolographic Analysis. **Epilepsia.** 44:8 (2003b) 1003-1013.

LUSZCZKI, J.J. [et al.] (2003c) - Interactions of Tiagabine with some antiepileptics in the maximal electroshock in mice. **Pharmacol. Biochem. Behav.** 75 (2003c) 319-327.

LUSZCZKI, J.J.; CZUCZWAR, S.J. (2003d) - Isobolographic and subthreshold methods in the detection of interactions between oxcarbazepine and conventional antiepileptics - a comparative study. **Epilepsy Res.** 56 (2003d) 27-42.

LUSZCZKI, J.J.; CZUCZWAR, S.J. (2004) - Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study. **Naunyn-Schmiedeberg's Arch Pharmacol.** 369 (2004) 434-446.

MACHADO, S.G.; ROBINSON, G.A. (1994) - A direct, general approach based on isobolograms for assessing the joint of drugs in pre-clinical experiments. **Stats. Med.** 13 (1994) 2289-2309.

MATAR, K.M. [et al.] (1999) - Effect of valproic acid on the pharmacokinetic profile of Oxcarbazepine in the rat. **Pharm. Acta Helv.** 73 (1999) 247-250.

MAY, T.W.; KORN-MERKER, E.; RAMBECK, B. (2003) - Clinical Pharmacokinetics of Oxcarbazepine. **Clin. Pharmacokinet.** 42:12 (2003) 1023-1042.

MCAULEY, J. [et al.] (2002) - Newer Therapies in the Drug Treatment of Epilepsy. **Ann. Pharmacother.** Jan. 36 (2002) 119-129.

MCLEAN, M.J. (1994) - Oxcarbazepine: mechanisms of action. **Epilepsia.** 35: Suppl. 3 (1994) S5-S9.

MILLER A.A. [et al.] (1986) - Pharmacological studies on Lamotrigine, a novel potential antiepileptic drug: I. Anticonvulsant profile in mice and rats. **Epilepsia.** 27:5 (1986) 483-489.

MILLER, A.A. [et al.] (1986a) - Lamotrigine. In MELDRUM, B.L.; PORTER, R.J., ed. Lit. - **Currents problems in epilepsy. 4-New antiepileptic drugs.** London: John Libbey & Co., 1986. Chapter 12:p.165-177.

NATSCHE, S. [et al.] (1997) - Newer Anticonvulsants Drugs: role of pharmacology, drug interactions and adverse reactions in drug choice. **Drug Saf.** Oct. 17:4 (1997) 228-240.

NOVACK, G.D.; STARK, L.G.; PETERSON, S. (1978) - Anticonvulsant effects of Bezdryl Piperazines on Maximal Electroshock seizures in Rats. **J. Pharm. Exp. Ther.** 208:3 (1978) 480-484.

PASCHOA, O.E.D. (1997) - Seizure patterns in Kindling and Cortical Stimulation models of experimental epilepsy. **Brain Res.** 770 (1997) 211-227.

PATSALOS, P.N.; DUNCAN, J.S. (1993) - Antiepileptic Drugs: A Review of Clinically Significant Drug Interactions. **Drug Saf.** 9:3 (1993) 156-184.

PATSALOS, P.N.; SANDER, J.W.A.S. (1994) - Newer Antiepileptic Drugs: Towards an improved Risk-Benefit Ratio. **Drug Saf.** 11:1 (1994) 37-67.

PATSALOS P.N. [et al.] (2002) - The importance of drug interactions in epilepsy therapy. **Epilepsia**. 43:4 (2002) 365-385.

PELOCK, J.M. (2000) - Treatment of Epilepsy in the New Millennium. **Pharmacotherapy**. 20:8 Pt. 2 (2000) 129S-138S.

PERUCCA E. (2002) - Marketed new antiepileptic drugs: are they better than old-generation agents? **Ther. Drug Monit.** 24 (2002) 74-80.

PERUCCA E. (2002) - Overtreatment in epilepsy: adverse consequences and mechanisms. **Epilepsy Res.** 52 (2002) 25-33.

PERUCCA E. (1995) - Pharmacological principles as a basis for polytherapy. **Acta Neurol. Scand.** Suppl. 162 (1995) 31-34.

PERUCCA E. (1996) - The New Generation Antiepileptic drugs: advantages and disadvantages. **Br. J. Clin. Pharmacol.** 42 (1996) 531-543.

Rambeck, B.; Specht, U.; Wolf, P. (1996) - Pharmacokinetic Interactions of New Antiepileptic Drugs. **Clin. Pharmacokinet.** Oct. 31:4 (1996) 309-324.

Rambeck, B.; Wolf, P. (1993) - Lamotrigine clinical pharmacokinetics. **Clin. Pharmacokinet.** 25:6 (1993) 433-443.

RATAUD, J. [et al.] (1994) - Comparative study of voltage-sensitive sodium channel blockers in focal ischaemia and electric convulsions in rodents. **Neurosci. Letters**. 172 (1994) 19-23.

RIVA, R. [et al.] (1996) - Pharmacokinetic Interactions between Antiepileptic Drugs. **Clin. Pharmacokinet.** Dec. 31:6 (1996) 470-493.

ROKS, G. [et al.] (1999) - Effects of Polytherapy Compared With Monotherapy in Antiepileptics Drugs: An Animal Study. **J. Pharmacol. Exp. Ther.** 288 (1999) 472-477.

SABERS, A.; GRAM, L. (2000) - Newer Anticonvulsants: comparative review of drug interactions and adverse efects. **Drugs**. Jul. 60:1 (2000) 23-33.

SMITH, P.E.M. (2001) – Clinical recommendations for oxcarbazepine. **Seizure.** 10 (2001) 87-91.

SCHMIDT, D.; GRAM, L. (1995) – Monotherapy versus Polytherapy in Epilepsy. **CNS Drugs.** 3:3 (1995) 194-208.

SCHMIDT, D. [et al.] (2001) – Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy: a consensus view. **Acta Neurol. Scand.** 104 (2001) 167-170.

SCHMIDT, D.; ELMER, C.; HOLMES, G.L. (2002) – Pharmacological overtreatment in epilepsy. Mechanisms and management. **Epilepsy Res.** 52 (2002a) 3-14.

SCHMIDT, D. (2002) – Strategies to prevent overtreatment with antiepileptic drugs in patients with epilepsy. **Epilepsy Res.** 52 (2002b) 61-69.

SCHMUTZ, M. [et al.] (1994) - Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action. **Epilepsia.** 35 Suppl. 5 (1994) S47-50.

SCHWABE, S. (1994) – Oxcarbazepine: clinical development program. **Epilepsia.** 35: Suppl. 5 (1994) S51-S53.

SCHWINGHAMMER, T. L.; KROBOTH P.D. (1988) – Basic concepts in pharmacodynamic modelling. **J. Clin. Pharmacol.** 28 (1988) 388-394.

STEPHEN, L.J., BRODIE, M.J. (2002) – Seizure freedom with more than one antiepileptic drug. **Seizure.** 11 (2002) 349-351.

STEINHOFF, B.J. [et al.] (2003) - The ideal characteristics of antiepileptic therapy: an overview of old and new AEDs. **Acta Neurol. Scand.** 107 (2003) 87-95.

SWIADER, M. [et al.] (2000) - Interaction of topiramate with conventional antiepileptic drugs in mice. **Eur. J. Pharmacol.** Jun. 30, 399:1 (2000) 35-41.

SWINYARD, E.A.; WOODHEAD, J.H.; WOLF, H.H. (1989) - Use of isobolograms in predicting drug interactions. In: PITLICK W, ed.

**Antiepileptic Drug Interactions.** Bethesda, MD: National Institute of Health. (1989).

SWINYARD, E.A.; KUPFERBERG, H.J. (1985) - Antiepileptic drugs: detection, quantification, and evaluation. **Federation Proc.** 44:10 (1985) 1-5.

TALLARIDA, R.J.; RAFFA, R.B. (1996) - Testing for synergism over a range of fixed ratio drug combinations: replacing the isobologram. **Life Sci.** 58:2 (1996) 23-28.

TALLARIDA, R.J.; [et al.] (1999) – Response surface analysis of synergism between morphine and clonidine. **J. Pharm. Exp. Ther.** 289 (1999) 8-13.

TALLARIDA, R.J. (2001) - Drug synergism: its detection and applications. **J. Pharm. Exp. Ther.** 298 (2001) 865-872.

TALLARIDA, R.J. (2002) - The interaction index: a measure of drug synergism. **Pain.** 98 (2002) 163-168.

TECOMA, E.S. (1999) – Oxcarbazepine. **Epilepsia.** 40: Suppl.5 (1999) S37-S46.

THOMSON, A.H.; BRODIE, M.J. (1992) - Pharmacokinetic Optimisation of Anticonvulsant Therapy. **Clin. Pharmacokinet.** 23:3 (1992) 216-230.

TOMAN, J.E.P.; SWINYARD, E.A.; GOODMAN, L.S. (1946) - Properties of maximal seizures, and their alteration by anticonvulsant drugs and other agents. **J. Neurophysiol.** 9 (1946) 231-240.

TRACY, A.; GLAUSSER, M.D. (2001) - Oxcarbazepine in the treatment of epilepsy. **Pharmacotherapy.** 21:8 (2001) 904-919.

UPTON, N. (1994) - Mechanisms of action of new antiepileptic drugs: rational design and serendipitous findings. **TIPS.** Dec. 15 (1994) 456-462.

VAN OPSTAL, J. M. [et al.] (2004) – Severe overdosage with the antiepileptic drug oxcarbazepine. **Br. J. Clin. Pharmacol.** 58:3 (2004) 320-331.

URE, J.A.; PERASSOLO. M.; (2000) - Update on the pathophysiology of the epilepsies - review article. **J. Neurolog. Sci.** 177 (2000) 1-17.

WAMIL, A.W. [et al.] (1994) - Effects of oxcarbazepine and 10-hydroxycarmazepine on action potential firing and generalized seizures. **Eur. J. Pharmacol.** 271 (1994) 301-308.

WHITE, H.S. (1999) - Comparative Anticonvulsant and Mechanistic Profile of the Established and Newer Antiepileptic Drugs. **Epilepsia.** 40 Suppl.5 (1999) S2-S10.

WHITE, H.S. (2003) - Preclinical Development of Antiepileptic Drugs: Past, Present and Future directions. **Epilepsia.** 44 Suppl. 7 (2003) 2-8.

WOLF, P. (1997). International Classification of the Epilepsies. In ENGEL, J.; PEDLEY,T.A. ed. lit. - **Epilepsy: A Comprehensive Textbook.** Philadelphia: Lippincott-Raven Publishers. (1997) Vol. 1 Chapter 68: p.773-777.

ZONA, C. [et al.]. (2002) - Neocortical potassium currents are enhanced by the antiepileptic drug Lamotrigine. **Epilepsia.** 43:7 (2002) 685-690.